

References

I-223

1. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. *Journal of Clinical Oncology*. 2017;35(19):2141-2148.
2. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. *N Engl J Med*. 2019;380:741-751.
3. Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132) an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. *Cancer*. 2017;123(19):3843-3854.
4. Trodelvy (sacituzumab govitecan-hziy) for injection, for intravenous use [package insert]. Immunomedics, Inc. Morris Plains, NJ. Revised 04/2021
5. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Sacituzumab govitecan-hziy. 2021
6. Micromedex® Solutions Compendia. 2021 Sacituzumab govitecan-hziy.
7. National Comprehensive Cancer Network (NCCN). Sacituzumab govitecan-hziy. NCCN Drugs and Biologics Compendium®. 2021.
8. Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, et al. TROPHY-U-01: A Phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol*. doi:10.1200/JCO.20.03489.
9. Sacituzumab Govitecan-hziy. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 11,2021.
10. Sacituzumab Govitecan. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.